XMT-1660: A Phase 1b trial of a B7-H4 targeting antibody drug conjugate (ADC) in endometrial, ovarian, and breast cancers

被引：0

作者：

Hamilton, Erika ^{[1
]}

Spira, Alexander ^{[2
]}

Adams, Sylvia ^{[3
]}

Abuhadra, Nour ^{[4
]}

Giordano, Antonio ^{[5
]}

Parajuli, Ritesh ^{[6
]}

Han, Hyo ^{[7
]}

Weise, Amy ^{[8
]}

Marchesani, Aubri ^{[9
]}

Josephs, Kate ^{[9
]}

Chaudhry, Arvind ^{[10
]}

Kalinsky, Kevin ^{[11
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN USA

[2] NEXT Oncol, Fairfax, VA USA

[3] NYU Langhone, Perlmutter Canc Ctr, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Dana Farber Canc Inst, Boston, MA USA

[6] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA USA

[7] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[8] Henry Ford Canc Inst, Detroit, MI USA

[9] Mersana Therapeut, Cambridge, MA USA

[10] Summit Canc Ctr, Spokane, WA USA

[11] Winship Canc Inst, Atlanta, GA USA

来源：

GYNECOLOGIC ONCOLOGY | 2023年 / 176卷

关键词：

D O I：

10.1016/j.ygyno.2023.06.159

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1250

引用

页码：S158 / S158

页数：1

共 50 条

[31] TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
de Bono, J. S.
Helissey, C.
Fizazi, K.
Maroto Rey, J. P.
Roubaud, G.
Antonarakis, E. S.
Sandhu, S. K.
Shore, N. D.
Ratta, R.
Perez Valderrama, B.
Vulsteke, C.
Schafer, L.
Marr, G.
Zhao, E.
Ward, A. F.
Piulats Rodriguez, J. M.
ANNALS OF ONCOLOGY, 2024, 35 : S996 - S997
[32] Expression of B7-H4 and IDO1 is Associated with Drug Response and Prognosis of High Grade Ovarian Serous Carcinoma
Niu, Na
Zhong, Yanping
Jazaeri, Amir
Sood, Anil
Liu, Jinsong
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1114 - 1115
[33] Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers
Song, Xinxin
Zhou, Zhuan
Li, Hongchun
Xue, Yifan
Lu, Xinghua
Bahar, Ivet
Kepp, Oliver
Hung, Mien-Chie
Kroemer, Guido
Wan, Yong
CANCER DISCOVERY, 2020, 10 (12) : 1872 - 1893
[34] Expression of B7-H4 and IDO1 is Associated with Drug Response and Prognosis of High Grade Ovarian Serous Carcinoma
Niu, Na
Zhong, Yanping
Jazaeri, Amir
Sood, Anil
Liu, Jinsong
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1114 - 1115
[35] Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Moore, Kathleen N.
O'Malley, David M.
Vergote, Ignace
Martin, Lainie P.
Gonzalez-Martin, Antonio
Malek, Karim
Birrer, Michael J.
GYNECOLOGIC ONCOLOGY, 2018, 151 (01) : 46 - 52
[36] Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma
Mao, Yurong
Wei, Ding
Fu, Fengqing
Wang, Huihui
Sun, Ziyu
Huang, Ziyi
Wang, Yan
Zhang, Guangbo
Zhang, Xueguang
Jiang, Biao
Chen, Hongli
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 257
[37] Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
Hamilton, E. P.
Barve, M. A.
Tolcher, A. W.
Buscema, J.
Papadopoulos, K. P.
Zarwan, C.
Anderson, C. K.
Doroshow, D.
Wang, D.
Huebner, D.
Jansen, V. M.
Jarlenski, D.
Mosher, R.
Kaufman, J.
Moore, K. N.
Richardson, D. L.
ANNALS OF ONCOLOGY, 2020, 31 : S627 - S628
[38] UPLIFT (ENGOT-OV67/GOG-3048) A PIVOTAL COHORT OF THE XMT-1536-1 TRIAL OF UPIFITAMAB RILSODOTIN (XMT-1536; UPRI), A NAPI2B-DIRECTED ANTIBODY DRUG CONJUGATE (ADC) IN PLATINUM-RESISTANT OVARIAN CANCER
Richardson, Debra
Perez Fidalgo, Jose Alejandro
Gonzalez-Martin, Antonio
Oaknin, Ana
Hamilton, Erika
Hays, John
Pothuri, Bhavana
Papadopoulos, Kyriakos
Taylor, Sara
Huang, Marilyn
Lee, Yeh-Chen
Krivak, Thomas
Moreno-Garcia, Victor
Calvo, Emiliano
Randall, Leslie
Starks, David
Ross, Malcom
Duska, Linda
Gao, Bo
Poka, Robert
Putiri, Emily
Barrett, Jamie
Demars, Leslie
Concin, Nicole
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A241 - A241
[39] Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer
Richardson, Debra L.
Moore, Kathleen N.
Vergote, Ignace
Gilbert, Lucy
Martin, Lainie P.
Mantia-Smaldone, Gina M.
Castro, Cesar M.
Provencher, Diane
Matulonis, Ursula A.
Stec, James
Wang, Yuemei
Method, Michael
O'Malley, David M.
GYNECOLOGIC ONCOLOGY, 2024, 185 : 186 - 193
[40] T-cell-engaging B7-H4/CD3 bispecific Fab-scFv antibody targeting human breast cancer
Iizuka, Akira
Ashizawa, Tadashi
Ohshima, Keiichi
Kusuhara, Masatoshi
Yamaguchi, Ken
Akiyama, Yasuto
CANCER SCIENCE, 2018, 109 : 413 - 413

← 1 2 3 4 5 →